Eton Pharmaceuticals, Inc. Inventory Write-down
Eton Pharmaceuticals, Inc. (ETON) reported Inventory Write-down of $581.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. inventory write-down for the quarter ending 2026-06-30 was $354.00K.
- Eton Pharmaceuticals, Inc. inventory write-down for the quarter ending 2026-03-31 was $227.00K, a 106.36% increase year-over-year.
- Eton Pharmaceuticals, Inc. inventory write-down for the quarter ending 2025-06-30 was $0.00.
- Eton Pharmaceuticals, Inc. inventory write-down for the quarter ending 2025-03-31 was $110.00K.
- Eton Pharmaceuticals, Inc. inventory write-down for fiscal 2025 was $594.00K, a 12.29% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. inventory write-down for fiscal 2024 was $529.00K, a 3426.67% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. inventory write-down for fiscal 2023 was $15.00K, a 75.81% decline from fiscal 2022.
- Eton Pharmaceuticals, Inc. inventory write-down for fiscal 2022 was $62.00K, a 95.62% decline from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $354.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $581.00K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $227.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $594.00K 10-K · filed 2026-03-19 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $110.00K 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $110.00K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $529.00K 10-K · filed 2026-03-19 | |||
| 2023-12-31 | $15.00K 10-K · filed 2026-03-19 | |||
| 2022-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$1.20M derived: sum of 2 quarters · filed 2023-03-16 | -$1.22M derived: sum of 3 quarters · filed 2023-03-16 | $62.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | -$1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.28M derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $982.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.26M 10-Q · filed 2022-08-11 | $2.25M derived: sum of 3 quarters · filed 2023-03-16 | |
| 2022-03-31 | $1.28M 10-Q · filed 2022-05-12 | $2.27M derived: sum of 2 quarters · filed 2023-03-16 | ||
| 2021-12-31 | $982.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.41M 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $432.00K 10-Q · filed 2021-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |